News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) Announces Chugai Pharmaceutical Co., Ltd. (Japan)'s Exercise of Japanese Development Rights for GDC-0449


2/18/2010 10:00:10 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Chugai Pharmaceutical Co., Ltd. (TSE: 4519) has exercised its right of first refusal for the development and commercialization in Japan of GDC-0449, a Hedgehog pathway inhibitor, under an existing agreement with F. Hoffmann-La Roche, Ltd (SIX: RO, ROG; OTCQX: RHHBY). GDC-0449 is being developed by Genentech, Inc., a wholly owned member of the Roche Group, under the 2003 collaboration agreement between Genentech and Curis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES